arrow
F

Francis Mhimbira

Utrecht University
H指数:26
被引数:3.6万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Sutezolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-SUDOCU-01): a prospective, open-label, randomised, phase 2b dose-finding trial

Sutezolid与bedaquiline、delamanid和moxifloxacin联合治疗肺结核(PanACEA-SUDOCU-01):一项前瞻性、开放标签、随机、Ⅱb期剂量探索试验

2025-07-080
OAAI
Delpazolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-DECODE-01): a prospective, randomised, open-label, phase 2b, dose-finding trial

德尔帕索利德联合贝达喹啉、德拉马尼和莫西沙星治疗肺结核(PanACEA-DECODE-01):一项前瞻性、随机、开放标签、IIb期剂量探索试验

2025-07-080
OAAI
Cardiac safety of bedaquiline, delamanid and moxifloxacin co-administered with or without varying doses of sutezolid or delpazolid for the treatment of drug-susceptible TB

Bedaquiline、Delamanid和Moxifloxacin与不同剂量的Sutezolid或Delpazolid联合或单独给药治疗药物敏感型结核病的 cardiac safety

2025-07-012
OA
Ultrasononography in Managing Extrapulmonary Tuberculosis: A Randomized, Controlled, Parallel, Superiority, Open-Label Trial

超声检查在肺外结核治疗中的应用: 一项随机,对照,平行,优越性,开放标签试验

2022-11-047
OAAI
The Sputum Microbiome in Pulmonary Tuberculosis and Its Association With Disease Manifestations: A Cross-Sectional Study

肺结核痰微生物组及其与疾病表现的关系: 一项横断面研究

2021-08-2014
OAAI
A partially randomised trial of pretomanid, moxifloxacin and pyrazinamide for pulmonary TB
2021-04-0135
OAAI
Mixed Th1 and Th2 Mycobacterium tuberculosis-specific CD4 T cell responses in patients with active pulmonary tuberculosis from Tanzania
2017-07-3137
OAAI
Measuring the health-related Sustainable Development Goals in 188 countries: a baseline analysis from the Global Burden of Disease Study 2015

衡量188国家与健康相关的可持续发展目标: 全球疾病负担研究2015的基线分析

LANCET
IF88.5
2016-10-01354
OAAI
Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015

全球,区域和国家的预期寿命,全因死亡率和249死因的原因特异性死亡率,1980 2015: 全球疾病负担研究2015的系统分析

LANCET
IF88.5
2016-10-013.7K
OAAI
Global, regional, national, and selected subnational levels of stillbirths, neonatal, infant, and under-5 mortality, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015

1980至2015死产、新生儿、婴儿和5岁以下儿童死亡率的全球、区域、国家和选定的次国家水平: 全球疾病负担研究2015的系统分析

LANCET
IF88.5
2016-10-01559
OAAI
Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015

全球,地区和国家315疾病和伤害的残疾调整寿命 (DALYs) 和健康预期寿命 (HALE),1990-2015: 全球疾病负担研究2015的系统分析

LANCET
IF88.5
2016-10-011.4K
OAAI
Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015

1990至2015 310疾病和损伤的全球、区域和国家发病率、患病率和残疾年限: 全球疾病负担研究2015的系统分析

LANCET
IF88.5
2016-10-012.9K
OAAI